J Cerebrovasc Endovasc Neurosurg > Epub ahead of print
Devanita S, Adhyatma, and Cahya: Risk factors of cerebral vasospasm associated with ruptured arterio-venous malformation: A systematic review and meta-analysis

Abstract

Objective

Cerebral vasospasm (CVS) could be an undetected reason for worsening condition in ruptured arteriovenous malformation (AVM) patients during the course. It is important to investigate the risk factors associated with vasospasm in order to establish preventive and therapeutic treatments in a timely manner. This study aimed to describe the risk factors of CVS associated with ruptured AVM.

Methods

We systematically searched electronic databases (PubMed, Science Direct, Cochrane Library, and SSRN) for studies assessing risk factors of CVS associated with spontaneous ruptured AVM. Risk factors assessed include demographic conditions, comorbidities, substance use, lab and vital parameters, and also the severity of bleeding. Meta-analysis was performed using data extracted from each study then Review Manager was used to analyze the risk ratio (RR) with 95% confidence intervals (95% CI).

Results

There were a total of 14 studies included. Chronic renal disease (RR=0.5 [95% CI 0.46-0.67]) and hyperlipidemia (RR=0.78 [95% CI 0.73-0.84]) as comorbid conditions both were found as protective factors. Then the use of substances, including smoking and stimulants, was found to tend to increase the incidence of CVS (RR=1.31 [95% CI 1.11-1.54] and RR=1.31 95% CI 1.11-1.51]) respectively. In the lab and vital parameters section, 8 of them showed results as risk factors for CVS, including leukocytosis (RR=1.58 [95% CI 1.35-1.84]), hyperglycemia (RR=1.17 [95% CI 1.07-1.29]), hyponatremia (RR=1.45 [95% CI 1.23-1.71]), hypokalemia (RR=1.28 [95% CI 1.20-1.36]), fever (RR=1.38 [95% CI 1.23-1.54]), hypovolemia (RR=1.39 [95% CI 1.15-1.67]), acute hypotension (RR=1.4 [95% CI 1.26-1.55]), and electrocardiogram (ECG) abnormality (RR=1.74 [95% CI 1.34-2.26]).

Conclusions

Chronic renal disease and hyperlipidemia were found as protective factors. Meanwhile, smoking, stimulant use, leukocytosis, hyperglycemia, hyponatremia, hypokalemia, fever, hypovolemia, acute hypotension, and ECG abnormalities are risk factors for CVS in patients with AVM rupture.

INTRODUCTION

Arteriovenous malformation (AVM)-associated bleeding seldom causes cerebral vasospasm (CVS) or delayed ischemic neurological deficits (DIND), which may deteriorate the patient’s condition unnoticed [9]. AVMs interrupt brain blood flow and oxygen circulation via tangles of blood vessels linking arteries and veins. When an AVM ruptures, it often leads to intracranial hemorrhage, increasing the risk of secondary neurological damage. CVS constitutes as one of the most serious complications in terms of patient morbidity and mortality [18]. It is defined as a condition of narrowing of the blood vessels in the brain that generally occurs on days 3-14 after bleeding (most often between days 6-8). The clinical symptoms are non-specific.
Recurrent headaches, altered awareness, disorientation, meningismus, and localized neurological abnormalities (cranial nerve paresis and focal motor deficits) are symptoms.11) The pathogenesis of CVS is multifocal and complex, and is not yet fully understood.
Vasospasm after AVM-related SAH is 1.9-12%, according to the literature. Up to 50% of angiographic vasospasm patients are asymptomatic, increasing mortality and neurological impairment, making early detection crucial. Recently, transcranial doppler (TCD) and computed tomography/magnetic resonance imaging (CT/MRI) cerebral angiography have improved vasospasm detection [36].
Vasospasm risk factors must be studied to develop preventative and therapeutic remedies quickly. However, CVS following SAH due to a ruptured AVM is uncommon, unconfirmed, and poorly understood. This research examined ruptured AVM-related CVS risk factors.

MATERIALS AND METHODS

Research question

PROSPERO (CRD420251037660) records this research. This study used the PECO framework [33].
- Populations: adults (≥18 years) diagnosed with ruptured AVM
- Exposure:
• Demographic conditions, including younger age, female gender, and moderate or severe Glasgow Coma Scale (GCS) on admission (<8)
• Comorbid conditions including hypertension, obesity, diabetes mellitus, chronic renal disease, hyperlipidemia
• Substance use, including smoking, stimulants, and alcohol
• Lab and vital parameters: leukocytosis, anemia, hyperglycemia, hyponatremia, hypokalemia, fever, increased blood pressure, hypovolemia, hypotension, electrocardiogram (ECG) abnormalities.
• Poor prognosis for hemorrhage severity, including Hunt and Hess grading (III, IV, V), Fisher/mFisher rating (mFisher 3-4), and infratentorial placement.
- Comparator: none
- Outcomes: the incidence of cerebral vasospasm

Design and search strategy

This systematic review and meta-analysis follows PRISMA. Spontaneous burst AVM risk factors for cerebral vasospasm were examined from conception until April 2025. PubMed, Science Direct, Cochrane Library, and SSRN were searched systematically. AVM, arteriovenous malformation, risk factor, vasospasm, and cerebral vasospasm were keywords.

Inclusion and exclusion criteria

Studies assessing vasospasm risk factors were considered. We only included patients aged >18 with spontaneous burst AVM. We exclude studies in case series or case report form, editorial, commentary, review, and those with no data. Only studies available in English were further analyzed.

Data extraction and statistical analysis

Rayyan.ai originally excluded publications that did not match qualifying requirements from titles and abstracts. The screening was done separately by LADS, IGRA, and KKDC. Discussing disagreements led to a consensus. Each research’s author, year, sample size, study design, patient demographics (age, sex), and cerebral vasospasm diagnostic technique were retrieved separately using a data extraction sheet.

Risk-of-bias assessment

For observational research, the ROBINS-E tool evaluated study quality [32]. Seven biases were assessed: confounding, participant selection, exposure categorization, deviations from planned exposures, missing data, outcome measurement, and result selection. Studies were categorized as low, some concerns, high, or extremely high for bias. The risk-of-bias evaluation was done separately by LADS, IGRA, and KKDC. If assessors disagreed, the majority assessment was given.

Data synthesis and statistical methods

Meta-analysis was done with Review Manager. To account for study variability, a REM was used. RRs and 95% CIs were determined for each treatment comparison. Heterogeneity was evaluated using the I² statistic, thresholds of 0-30%, 31-50%, and >50% indicating insignificant, moderate, and considerable heterogeneity. Network consistency was assessed using the Q-statistic and the design-by-treatment interaction model.

RESULTS

Study selection and characteristics

A total of 972 records were identified, with 21 duplicates removed, leaving 951 for screening. Of these, 493 were excluded, and 458 reports were sought for retrieval. 443 were not retrieved, resulting in 15 reports assessed for eligibility. After full-text review, 9 were excluded, leaving 14 studies included. Additionally, 396 records were identified through citation searching, 22 were assessed for eligibility after 374 were not retrieved, with 14 subsequently excluded. The PRISMA flowchart is shown in Fig. 1.
All included were observational, including prospective cohort, retrospective cohort, retrospective case control, and cross-sectional. Out of 16,304 individuals, 7,095 were in the vasospasm group and 9,209 were not. Two multi-center studies were undertaken, although most were single-center. Baseline population and clinical characteristics are presented in Tables 1 and 2.

Risk of bias assessment

The traffic light graphic (Fig. 2) shows how the ROBINS-E tool evaluated bias in the observational studies. Each domain has low bias (green), moderate concerns (yellow), or substantial bias (red).
In general, most studies included in the review demonstrated some concerns (yellow) across several domains. Specifically, all studies except one showed some concerns in domains related to confounding (D1), postinterventions (D4), missing (D5), and selection reported results (D7). Notably, Chhor et al., 2011 had a high risk in both the confounding domain (D1) and the selection of participants domain (D3), suggesting methodological shortcomings that may impact their results. In contrast, domains D2 (exposure measurement) and D6 (outcome measurement) has little bias (green) in most trials, indicating good exposure and outcome assessment.
Overall, while the majority of studies presented certain methodological concerns, no study (other than Chhor et al., 2011) has a high overall risk of bias. These findings suggest that although the evidence base includes studies with some limitations, most studies provide reasonably reliable estimates, albeit with some caution due to potential residual confounding and reporting biases.

Outcomes

After data extraction was carried out, 2 of the 24 exposures were only included in one study, making it impossible to draw conclusions using the meta-analysis method, including younger age and obesity comorbid conditions. In addition (22 of 24 exposures), conclusions were drawn using an analysis method with visualization using a forest plot as follows (Figs. 3-17). Given the limited number and heterogeneity of included studies, these analyses are considered exploratory. Definitions of vasospasm varied across studies, including angiographic, transcranial Doppler-based, and clinical criteria. Significance was obtained for 12 exposures, including chronic renal disease, hyperlipidemia, smoking, stimulant use, leukocytosis, hyperglycemia, hyponatremia, hypokalemia, fever, hypovolemia, acute hypotension, and ECG abnormalities.
Chronic renal disease (RR= 0.5 [95% CI 0.46-0.67] p-v <0.0001) and hyperlipidemia (RR=0.78 [95% CI 0.73-0.84] p-v <0.00001) as comorbid conditions were both found as protective factors. Then the use of substances, including smoking and stimulants, was found to tend to increase the incidence of CVS (RR=1.31 [95% CI 1.11-1.54] p-v=0.001), RR=1.31 [95% CI 1.11-1.51] p-v=0.0002) respectively. In the lab and vital parameters section, 8 of them showed results as risk factors for CVS, including leukocytosis (RR=1.58 [95% CI 1.35-1.84] p-v<0.0001), hyperglycemia (RR=1.17 [95% CI 1.07-1.29] p-v=0.0009), hyponatremia (RR=1.45 [95% CI 1.23-1.71] p-v<0.0001), hypokalemia (RR=1.28 [95% CI 1.20-1.36] p-v<0.00001), fever (RR=1.38 [95% CI 1.23-1.54] p-v<0.00001), hypovolemia (RR=1.39 [95% CI 1.15-1.67] p-v=0.006), hypotension (RR=1.4 [95% CI 1.26-1.55] p-v<0.00001), ECG abnormality (RR=1.74 [95% CI 1.34-2.26] p-v<0.0001).

DISCUSSION

Protective factors

Interestingly, chronic renal disease (CRD) and hyperlipidemia were associated with a lower incidence of CVS. This finding may be related to intrinsic vascular alterations. In CRD, chronic endothelial dysfunction may lead to reduced vascular responsiveness to acute vasoconstrictive stimuli [2,37], while uremia-related immunomodulation may attenuate inflammatory pathways involved in vasospasm [5,19,38]. Similarly, hyperlipidemia may be associated with structural vascular changes, such as increased arterial stiffness and adaptive endothelial responses, potentially reducing susceptibility to acute vasoconstriction [27]. Although concomitant use of vasoactive medications and statins may contribute to this association, medication use was not consistently reported across studies [7,14,23,34]. Therefore, any contribution of these therapies remains uncertain, and the observed associations should be interpreted with caution.

Substances use

The use of substances, specifically smoking and stimulants, was found to significantly increase the incidence of CVS. These agents activate the sympathetic nervous system and directly induce cerebral vasoconstriction [1,31]. Smoking introduces nicotine and carbon monoxide, which impair endothelial function and promote catecholamine-mediated vasospasm [4,21,39]. Similarly, stimulant drugs (e.g., cocaine, amphetamines) trigger acute vasospastic crises via intense adrenergic surges and direct smooth muscle stimulation [6,8,10,31].

Laboratory and vital parameters associated factors

Several laboratory and clinical indicators were linked to cerebral vasospasm. Leukocytosis may indicate a high systemic inflammatory state, which causes vasospasm via cytokine-mediated endothelial dysfunction and oxidative stress [15,20]. Similarly, hyperglycemia may worsen vascular injury by promoting endothelial cell apoptosis and impairing nitric oxide production, thereby enhancing vasoreactivity [28,41].
CVS risk increases with electrolyte abnormalities. Syndrome of inappropriate antidiuretic hormone (SIADH) frequently causes hyponatremia and hypokalemia in neurocritical care. These disturbances can lead to hypovolemia and neuronal excitability, both of which increase cerebrovascular tone and predispose to vasospasm [3,24,29].
Fever, whether infectious or neurogenic in origin, may further exacerbate the inflammatory cascade and compromise cerebral autoregulation, thereby increasing vasospastic risk [22]. Moreover, hypovolemia and acute hypotension were shown to significantly impair cerebral perfusion pressure, potentially triggering compensatory vasoconstriction in vulnerable arterial segments [25,26,30,35].
Lastly, electrocardiographic abnormalities, which may reflect autonomic dysregulation or neurocardiogenic injury following subarachnoid hemorrhage, serve as a clinical indicator of increased sympathetic drive another key contributor to cerebral vasospasm [13,14,16,17,40]. These results emphasize the need for monitoring metabolic and hemodynamic stability in ruptured AVM patients, as these parameters are not merely epiphenomena but may actively contribute to vasospastic pathophysiology.
In contrast to aneurysmal subarachnoid hemorrhage, vasospasm following AVM rupture may arise through different mechanisms, particularly in the absence of diffuse subarachnoid hemorrhage. In such cases, vasospasm may be driven by localized effects of intracerebral or intraventricular hemorrhage, including the accumulation of blood breakdown products, focal inflammatory responses, and direct microvascular irritation. These mechanisms may result in more focal, angiographic, or subclinical vasospasm rather than the diffuse patterns typically observed in aneurysmal subarachnoid hemorrhage [9,12].
Most included studies reported unadjusted associations without controlling for important confounders such as hemorrhage severity, AVM characteristics, and treatment factors, limiting causal inference. Therefore, the observed relationships should be interpreted as associations rather than causal effects. Some variables, such as leukocytosis, electrolyte imbalance, and hypotension, may reflect disease severity or downstream responses rather than independent risk factors.
In addition, angiographic and hemorrhage patterns, such as subarachnoid, intracerebral, and intraventricular hemorrhage, were not consistently analyzed across the included studies. Diffuse subarachnoid hemorrhage is a well-established risk factor for vasospasm and may act as an important confounder. The lack of stratification by hemorrhage pattern may therefore influence the observed associations and should be considered when interpreting the results.

Strengths and limitations

This study used a comprehensive search strategy with independent data extraction and risk of bias assessment, enhancing reliability. However, several limitations should be noted. The small number of included studies and their heterogeneity in design, populations, and diagnostic criteria may limit the strength of the analysis. Several exposures were derived from only one or two studies, reducing the reliability of pooled estimates. Residual confounding and selection bias are likely due to the observational nature of the included studies and the lack of adjustment for key variables, including medication use. Most analyses were based on unadjusted data, limiting causal inference, and some variables may reflect disease severity rather than independent risk factors. In addition, heterogeneous definitions of vasospasm and inconsistent reporting of hemorrhage patterns may introduce misclassification and confounding. The use of multiple forest plots may also overrepresent the apparent precision of the findings; therefore, results should be considered exploratory and interpreted with caution.

CONCLUSIONS

Chronic renal disease and hyperlipidemia were associated with a lower incidence of vasospasm, however, these findings should be interpreted with caution due to potential residual confounding and lack of adjustment for medication-related factors. Meanwhile, smoking, stimulant use, leukocytosis, hyperglycemia, hyponatremia, hypokalemia, fever, hypovolemia, acute hypotension, and CVS risk factors in AVM rupture patients include ECG abnormalities. These findings should be interpreted with caution, given the limited and heterogeneous evidence base.

Supplementary

NOTES

Disclosures

The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Fig. 1.
PRISMA chartflow of the study included selection.
jcen-2026-e2025-12-003f1.jpg
Fig. 2.
Risk of bias assessment
jcen-2026-e2025-12-003f2.jpg
Fig. 3.
Forest plot of chronic renal disease.
jcen-2026-e2025-12-003f3.jpg
Fig. 4.
Forest plot of hyperlipidemia.
jcen-2026-e2025-12-003f4.jpg
Fig. 5.
Forest plot of smoking.
jcen-2026-e2025-12-003f5.jpg
Fig. 6.
Forest plot of stimulant use as risk factors.
jcen-2026-e2025-12-003f6.jpg
Fig. 7.
Forest plot of leukocytosis.
jcen-2026-e2025-12-003f7.jpg
Fig. 8.
Forest plot of hyperglycemia.
jcen-2026-e2025-12-003f8.jpg
Fig. 9.
Forest plot of hyponatremia.
jcen-2026-e2025-12-003f9.jpg
Fig. 10.
Forest plot of hypokalemia as a risk fator.
jcen-2026-e2025-12-003f10.jpg
Fig. 11.
Forest plot of fever.
jcen-2026-e2025-12-003f11.jpg
Fig. 12.
Forest plot of hypovolemia.
jcen-2026-e2025-12-003f12.jpg
Fig. 13.
Forest plot of acute hypotension.
jcen-2026-e2025-12-003f13.jpg
Fig. 14.
Forest plot of ECG abnormality.
jcen-2026-e2025-12-003f14.jpg
Fig. 15.
Forest plot of Hunt and Hess grading III, IV, or V.
jcen-2026-e2025-12-003f15.jpg
Fig. 16.
Forest plot of mFisher 3-4 grading as risk factors.
jcen-2026-e2025-12-003f16.jpg
Fig. 17.
Forest of infratentorial bleeding location as risk factors.
jcen-2026-e2025-12-003f17.jpg
Table 1.
Baseline population characteristics
No Author, Year Country Study design Single/Multi center Total population (n) With vasospasm (n) Without vasospasm (n) Gender
Age
Radiological imaging Admission features
GCS on admission
Seizure
Male (n) Female (n) With vasospasm (mean, SD) Without vasospasm (mean, SD) With vasospasm Without vasospasm
1 Arias et al., 2017 Colombia Observational retrospective case-control study Single-center 141 47 94 46 95 50.1±11.8 58.2±10.8 SAH (n=141) Mild (n=38 [81%]) Mild (n=69 [73%]) N/A
Moderate (n=6 [13%]) Moderate (n=10 [11%])
Serious (n=3 [6%]) Serious (n=15 [16%])
2 Chhor et al., 2011 France Observational cohort study Single-center 72 12 60 43 29 40±9 SAH (diffuse (n=14 [19%]) <8 (n=28 [39%]) With vasospasm (n=2)
focal (n=18 [25%])
absent (n=40 [56%]) ≥8 (n=44 [61%]) Without vasospasm (n=7)
ICH (n=64 [89%])
IVH (n=54 [75%])
3 Dicpinigaitis et al., 2022 New Mexico Cross-sectional analysis study Multi-center 7,215 935 6,280 3,510 3,705 52.4±0.4 55.9±0.2 SAH (n=5,180 [71.8%]) <9 (n=405) N/A
IVH (n=1,165 [16.1%]) ≥9 (n=6,810)
4 Dinc et al., 2019 Germany Observational retrospective study Single-center 160 6 154 80 80 42 (2-82) With IVH (n=78) >12 (n=106) N/A
Without IVH (n=82) ≤12 (n=54)
5 Inagawa et al., 2014 Japan Observational cohort prospective study Single-center 370 95 275 N/A N/A SAH alone (n=317) N/A N/A
ICH or/and IVH (n=50)
6 Rumalla et al., 2020 USA Population-based, retrospective cohort study Multi center 8,346 6,000 2,346 2,420 5,925 18-47 (n=2,148) With IVH (n=1,232) N/A N/A
48-57 (n=2,241)
51-74 (n=2,163) With ICH (n=356)
75-99 (n=1,794)
7 Amuluru et al., 2018 New Jersey, USA Institutional-based, retrospective cohort study Single-center 36 5 31 20 16 62 40 With IPH (n=27) N/A N/A
With SAH (n=15)
With IVH (n=26)
8 Charpentier et al., 1999 France Institutional-based, retrospective cohort study Single-center 244 47 197 98 146 >50 (n=16) >50 (n=101) N/A N/A N/A
9 Gollwitzer et al., 2025 Austria Institutional-based, retrospective cohort study Single-center 345 189 156 109 236 52.4±12 60±13 N/A N/A N/A
10 Khan et al., 2022 Qatar Institutional-based, retrospective cohort study Single-center 259 87 172 177 82 47.9±12.9 46.3±11.77 With IVH (n=121) N/A N/A
With ICH (n=16)
With ICerebellarH (n=50)
11 Nathani et al., 2026 USA Population-based, retrospective cohort study Single-center 7,652 1,913 5,739 1,913 5,354 53.6±12.67 53.6±14.84 N/A N/A N/A
12 Opancina et al., 2020 Serbia Institutional-based, retrospective cohort study Single-center 66 33 33 18 48 55.45±12.13 52.55±9.55 With IVH (n=23) 11.15±3.58 11.09±3.15 N/A
13 Rao et al., 2025 USA Institutional-based, retrospective cohort study Single-center 88 38 50 22 66 53 (2) 55 (2) N/A N/A N/A N/A
14 Kim et al., 2021 Korea Institutional-based, retrospective cohort study Single-center 343 56 287 134 209 55.45±13.2 N/A N/A N/A N/A

n, number; SD, standard deviation; GCS, Glasgow Coma Scale; SAH, subarrachnoid haemorrhage; ICH, intracerebral haemorrhage; IVH, intraventricular haemorrhage; N/A, not available

Table 2.
Clinical characteristics
Clinical classification
Site of aneurysm Size of AVM Treatment of AVM rupture Mortality
WFNS Grading
Hunt and Hess Grading
mFisher Scale
With vasospasm Without vasospasm With vasospasm Without vasospasm With vasospasm Without vasospasm With vasospasm (n) Without vasospasm (n)
Good prognosis (grades I, II, III) (n=37 [79%]) Good prognosis (grades I, II, III) (n=71 [76%]) Good prognosis (grades I, II) (n=31 [66%]) Good prognosis (grades I, II) (n=63 [69%]) Grade 0 (n=2 [4%]) Grade 0 (n=11 [12%]) N/A N/A Not well described 19% 9%
Grade 1 (n=11 [23%]) Grade 1 (n=23 [25%])
Poor prognosis (grades III, IV, V) (n=10 [21%]) Poor prognosis (grades III, IV, V) (n=23 [24%]) Poor prognosis (grades III, IV, V) (n=16 [34%]) Poor prognosis (grades III, IV, V) (n=31 [31%]) Grade 2 (n=3 [6%]) Grade 2 (n=12 [13%])
Grade 3 (n=16 [34%]) Grade 3 (n=19 [20%])
Grade 4 (n=15 [32%]) Grade 4 (n=29 [30%])
N/A N/A N/A Frontal (n=25 [35%]) The timing and type of treatment (embolization, surgical resection, or both) were decided by consensus between the neurosurgeon and intervetional neuroradiologist based on the clinical presentation and on the location (surgical resection (n=32 [49%]), embolization (n=15 [20%]), mixed (n=6 [8%]) 5 10
Temporal (n=10 [14%]) <3 cm (n=43 [63%])
Parietal (n=15 [21%]) 3-6 cm [n=19 [28%])
Occipital (n=8 [11%]) >6 cm (n=6 [8%])
Posterior fossa (n=14 [19%])
N/A N/A N/A N/A N/A N/A 60 420
N/A N/A Grade 0 (n=78 [49%]) Supratentorial (n=111) N/A N/A N/A
Grade 1 (n=23 [14%])
Grade 2 (n=9 [6%]) Infratentorial (n=49)
Grade 3 (n=10 [6%])
Grade 4 (n=40 [25%])
N/A I-II (n=202) N/A N/A N/A All treated surgically N/A
III-IV (n=168)
N/A HH 1 (SSS 0-0.5) (n=2,472 [29.6%) N/A Pcom (n=1,952 [23.4%]) N/A Coiling (n=6,245 [74.8%]) N/A
Acom (n=782 [9.4%])
HH 2 (SSS 0.5-2) (n=1,009 [12.1%]) MCA (n=1,204 [14.4%])
HH 3 (SSS 2-6) (n=1,088 [13.0%]) Carotid siphon/bifurcation (n=383 [4.6%]) Clipping (n=2,447 [25.2%])
HH 4 (SSS 6-9) (n=1,560 [18.7%]) Basilar [n=585 [7%])
HH 5 (SSS 9+) (n=2,218 [26.6%]) Vertebral (n=182 [2.2])
Other/unspecified (n=3,258 [4.3%])
N/A N/A N/A N/A N/A N/A
WFNS >2 (n=10) WFNS >2 (n=59) HH >2 (n=10) HH >2 (n=88) mFisher >2 (n=36) mFisher >2 (n=138) Posterior circulation (n=41) N/A Surgical (n=99) N/A N/A
Ventricular drainage (n=54)
N/A N/A HH 1 (n=30) HH 1 (n=47) mFisher 1 (n=5) mFisher 1 (n=4) ACA (n=35) Max diameter: 6.1 (3.5) mm Clipping (n=47) N/A N/A
Acom (n=120)
AICA (n=1)
BA (n=23)
HH 2 (n=58) HH 2 (n=55) mFisher 2 (n=5) mFisher 2 (n=20) ICA (n=37)
HH 3 (n=41) HH 3 (n=28) mFisher 3 (n=58) mFisher 3 (n=54) MCA (n=69) Dome height: 4.9 (2.99) mm Coiling (n=288)
HH 4 (n=50) HH 4 (n=19) mFisher 4 (n=121) mFisher 4 (n=78) PCA (n=5) Untreated (n=10)
HH 5 (n=10) HH 5 (n=7) Pcom (n=39)
PICA (n=10)
SCA (n=1)
VA (n=5)
WFNS 1 (n=18) WFNS 1 (n=76) HH 1 (n=14) HH 1 (n=69) mFisher 1 (n=14) mFisher 1 (n=47) Acom (n=91) N/A Clipping (n=50) N/A N/A
Vertebral (n=4)
MCA (n=71)
WFNS 2 (n=28) WFNS 2 (n=45) HH 2 (n=33) HH 2 (n=57) Basilar (n=6)
WFNS 3 (n=4) WFNS 3 (n=49) HH 3 (n=13) HH 3 (n=14) mFisher 2 (n=22) mFisher 2 (n=49) ACA (n=8)
WFNS 4 (n=20) WFNS 4 (n=20) HH 4 (n=12) HH 4 (n=12) mFisher 3 (n=10) mFisher 3 (n=16) ICA (n=25) Coiling (n=104)
WFNS 5 (N=11) WFNS 5 (N=17) HH 5 (n=10) HH 5 (n=16) mFisher 4 (n=38) mFisher 4 (n=55) PCA (n=3)
SCA (n=1)
PCom (n=26)
Callosm (n=1)
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A ICA (n=25) Max diameter: 5.49 (3.36) mm N/A N/A N/A
MCA (n=10)
ACA (n=23) Dome height: 6.71 (3.85) mm
PCA (n=4)
BA (n=4)
N/A N/A 3±1.05 2±0.96 3±0.654 3±1.04 ACA (n=25) N/A N/A N/A N/A
ICA (n=26)
MCA (n=20)
Posterior circulation (n=15)
N/A N/A HH 1 (n=15) mFisher 1 (n=22) ICA (n=12) N/A N/A N/A N/A
PCA (n=69)
HH 2 (n=162) mFisher 2 (n=29) ACA (n=17)
HH 3 (n=88) mFisher 3 (n=138) ICA (n=3)
HH 4 (n=67) mFisher 4 (n=153) MCA (n=69)
HH 5 (n=11) Acom (n=118)
DACA (n=12)

ICA, internal carotid artery; ACA, anterior cerebral arteries; DACA, distal anterior cerebral artery; Acom, anterior communicating artery; MCA, middle cerebral artery; BA, basilar artery; PCA, posterior cerebral artery; Pcom, posterior communicating artery; SCA, superior cerebellar artery; AICA, anterior inferior cerebellar artery; PICA, posterior inferior cerebellar artery; AVM, arteriovenous malformation; WFNS, World Federation of Neurological Surgeons; mFisher, modified Fisher; HH, Hunt and Hess; n, number; N/A, not available

REFERENCES

1. Avola G, Pezzini A. Treatment-related reversible cerebral vasoconstriction syndrome. J Clin Med. 2024 Oct;13(19):5930.
crossref pmid pmc
2. Baaten CC, Vondenhoff S, Noels H. Endothelial cell dysfunction and increased cardiovascular risk in patients with chronic kidney disease. Circ Res. 2023 Apr;132(8):970-92.
crossref pmid pmc
3. Bhat R, Baldeweg SE, Wilson SR. Sodium disorders in neuroanaesthesia and neurocritical care. BJA Educ. 2022 Dec;22(12):466-73.
crossref pmid pmc
4. Choi YK, Kim YM. Regulation of endothelial and vascular functions by carbon monoxide via crosstalk with nitric oxide. Front Cardiovasc Med. 2021 Apr;8:649630.
crossref pmid pmc
5. Chermiti R, Burtey S, Dou L. Role of uremic toxins in vascular inflammation associated with chronic kidney disease. J Clin Med. 2024 Nov;13(23):7149.
crossref pmid pmc
6. Conway JE, Tamargo RJ. Cocaine use is an independent risk factor for cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke. 2001 Oct;32(10):2338-43.
crossref pmid
7. Demir E, Eras MA, Bilge T. The effect of the ACE inhibitor lisinopril on cerebral vasospasm after experimental subarachnoid hemorrhage. Haydarpaşa Numune Medical Journal. 2025;65(1):8-13.
crossref
8. den Uil CA, Ligthart JMR, Mandigers L, den Dekker WK. Cocaine/amphetamine-induced accelerated atherosclerosis, coronary spasm and thrombosis, and refractory ventricular fibrillation. Eur Heart J Case Rep. 2019 Dec;3(4):1-2.
crossref pdf
9. Dinc N, Won SY, Eibach M, Quick-Weller J, Konczalla J, Berkefeld J, et al. Cerebral vasospasm due to arteriovenous malformation-associated hemorrhage: Impact of bleeding source and pattern. J Cerebrovasc Endovasc Neurosurg. 2019;47(3-4):165-70.
crossref pdf
10. Florez-Perdomo WA, Reyes Bello JS, García-Ballestas E, Moscote-Salazar LR, Barthélemy EJ, Janjua T, et al. Aneurysmal subarachnoid hemorrhage and cocaine consumption: A systematic review and meta-analysis. World Neurosurg. 2024 Apr;184:241-52.
pmid
11. Frontera J, Fernandez A, Schmidt J. Defining vasospasm after subarachnoid hemorrhage: What is the most clinically relevant definition? Stroke. 2009 Jun;40:1963-8.
crossref pmid
12. Gross B, Du R. Vasospasm after arteriovenous malformation rupture. World Neurosurg. 2012 Sep-Oct;78(3-4):300-5.
crossref pmid
13. Hasegawa Y, Uchikawa H, Kajiwara S, Morioka M. Central sympathetic nerve activation in subarachnoid hemorrhage. J Neurochem. 2021 Oct;160(1):34-50.
crossref pmid pdf
14. Herman LL, Padala SA, Ahmed I, Bashir K. Angiotensin-converting enzyme inhibitors (ACEI) [updated 2023 Jul 31]. In: StatPearls. 2025 Jan-.
15. Higashi Y. Roles of oxidative stress and inflammation in vascular endothelial dysfunction-related disease. Antioxidants. 2022 Sep;11(10):1958.
crossref pmid pmc
16. Hooglugt A, Klatt O, Huveneers S. Vascular stiffening and endothelial dysfunction in atherosclerosis. Curr Opin Lipidol. 2022 Dec;33(6):353-63.
crossref pmid pmc
17. Ibrahim GM, Macdonald RL. Electrocardiographic changes predict angiographic vasospasm after aneurysmal subarachnoid hemorrhage. Stroke. 2012 Aug;43(8):2102-7.
crossref pmid
18. Inagawa T, Yahara K, Ohbayashi N. Risk factors associated with cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Neurol Med Chir (Tokyo). 2014 Jun;54(6):465-73.
crossref pmid pmc
19. Jha PK, Nakano T, Itto LYU, Barbeiro MC, Lupieri A, Aikawa E, et al. Vascular inflammation in chronic kidney disease: The role of uremic toxins in macrophage activation. Front Cardiovasc Med. 2025 Mar;12:1574489.
crossref pmid pmc
20. Joffre J, Hellman J. Oxidative stress and endothelial dysfunction in sepsis and acute inflammation. Antioxid Redox Signal. 2021 Nov;35(15):1291-307.
crossref pmid pdf
21. Klein J, Diaba-Nuhoho P, Giebe S, Brunssen C, Morawietz H. Regulation of endothelial function by cigarette smoke and next-generation tobacco and nicotine products. Pflugers Arch. 2023 Jul;475(7):835-44.
crossref pmid pmc pdf
22. Lai PMR, See AP, Silva MA, Gormley WB, Frerichs KU, Aziz-Sultan MA, et al. Noninfectious fever in aneurysmal subarachnoid hemorrhage: Association with cerebral vasospasm and clinical outcome. World Neurosurg. 2019 Feb;122:e1014-9.
crossref pmid
23. Lee SU, Byoun HS, Cho MJ, Lim JW, Kim CH, Bang JS. Preventative effect of angiotensin receptor blockers on moderate-to-severe cerebral vasospasm among patients who received interventions for aneurysmal subarachnoid hemorrhage. Biomedicines. 2025 Feb;13(2):442.
crossref pmid pmc
24. Lerner DP, Shepherd SA, Batra A. Hyponatremia in the neurologically ill patient: A review. Neurohospitalist. 2020 Jul;10(3):208-16.
crossref pmid pmc pdf
25. Lidington D, Wan H, Bolz SS. Cerebral autoregulation in subarachnoid hemorrhage. Front Neurol. 2021 Jul;12:688362.
crossref pmid pmc
26. Ling YH, Chi NF, Pan LH, Wang YF, Wu CH, Lirng JF, et al. Association between impaired dynamic cerebral autoregulation and BBB disruption in reversible cerebral vasoconstriction syndrome. J Headache Pain. 2023 Dec;24(1):170.
crossref pmid pmc pdf
27. Liu JC, Lei SY, Zhang DH, He QY, Sun YY, Zhu HJ, et al. The pleiotropic effects of statins: A comprehensive exploration of neurovascular unit modulation and blood-brain barrier protection. Mol Med. 2024 Dec;30(1):256.
crossref pmid pmc pdf
28. Liu Z, Lu J, Sha W, Lei T. Comprehensive treatment of diabetic endothelial dysfunction based on pathophysiological mechanism. Front Med (Lausanne). 2025 Feb;12:1509884.
crossref pmid pmc
29. Mezzini G, Marasco S, Bertuccio A, Savioli G, Piccolella F, Racca F, et al. Hyponatremia related to neurocritical care: Focus on diagnosis and therapy: A systematic review. Rev Recent Clin Trials. 2023;18(1):19-27.
crossref pmid pdf
30. Meng L. Heterogeneous impact of hypotension on organ perfusion and outcomes: A narrative review. Br J Anaesth. 2021 Dec;127(6):845-61.
crossref pmid pmc
31. Middlekauff HR, Cooper ZD, Strauss SB. Drugs of misuse: Focus on vascular dysfunction. Can J Cardiol. 2022 Sep;38(9):1364-77.
crossref pmid pmc
32. Morgan R, Thayer K, Santesso N, Holloway AC, Blain R, Eftim SE, et al. A risk of bias instrument for non-randomized studies of exposures: A users’ guide to its application. Environ Int. 2019 Jan;122:168-84.
pmid
33. Morgan R, Whaley P, Thayer K, Schünemann HJ. Identifying the PECO: A framework for formulating good questions to explore the association of environmental and other exposures with health outcomes. Environ Int. 2018 Dec;121(1):1027-31.
crossref pmid pmc
34. Morofuji Y, Nakagawa S, Ujifuku K, Fujimoto T, Otsuka K, Niwa M, et al. Beyond lipid-lowering: Effects of statins on cardiovascular and cerebrovascular diseases and cancer. Pharmaceuticals (Basel). 2022 Jan;15(2):151.
crossref pmid pmc
35. Owens WB. Blood pressure control in acute cerebrovascular disease. J Clin Hypertens (Greenwich). 2011 Mar;13(3):205-11.
crossref pmid
36. Rodríguez P, Rodríguez L, Rodríguez D. Diagnóstico de la isquemia cerebral tardía y el vasospasmo cerebral en la hemorragia subaracnoidea. Neurologia. 2010 Jun;25:322-30.
crossref pmid
37. Roumeliotis S, Mallamaci F, Zoccali C. Endothelial dysfunction in chronic kidney disease, from biology to clinical outcomes: A 2020 update. J Clin Med. 2020 Jul;9(8):2359.
crossref pmid pmc
38. Six I, Flissi N, Lenglet G, Louvet L, Kamel S, Gallet M, et al. Uremic toxins and vascular dysfunction. Toxins (Basel). 2020 Jun;12(6):404.
crossref pmid pmc
39. Whitehead AK, Erwin AP, Yue X. Nicotine and vascular dysfunction. Acta Physiol (Oxf). 2021 Apr;231(4).e13631.
crossref pmid pmc pdf
40. Wybraniec MT, Mizia-Stec K, Krzych Ł. Neurocardiogenic injury in subarachnoid hemorrhage: A wide spectrum of catecholamin-mediated brain-heart interactions. Cardiol J. 2014;21(3):220-8.
crossref pmid
41. Yang DR, Wang MY, Zhang CL, Wang Y. Endothelial dysfunction in vascular complications of diabetes: A comprehensive review of mechanisms and implications. Front Endocrinol (Lausanne). 2024 Apr;15:1359255.
crossref pmid pmc


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
The Journal of Cerebrovascular and Endovascular Neurosurgery (JCEN), Department of Neurosurgery, Wonkwang University
School of Medicine and Hospital, 895, Muwang-ro, Iksan-si, Jeollabuk-do 54538, Korea
Tel: +82-2-2279-9560    Fax: +82-2-2279-9561    E-mail: editor.jcen@the-jcen.org                

Copyright © 2026 by Korean Society of Cerebrovascular Surgeons and Korean NeuroEndovascular Society.

Developed in M2PI

Close layer
prev next